TBPH vs GLUE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
TBPH · Theravance Biopharma(Delisted)$0.00 ▲ 0.00%
GLUE · Monte Rosa Therapeutics$10.57 ▲ 3.12%
Head to head
| Metric | TBPH | GLUE |
|---|---|---|
| Price | $0.00 | $10.57 |
| Change today | ▲ 0.00% | ▲ 3.12% |
| Market cap | $884.18M | $903.21M |
| Return, 3 months | – | -33.2% |
| Return, year to date | – | -32.6% |
| Return, 1 year | – | -14.1% |
| P/E (TTM) | 16.4 | – |
| P/B | 3.1 | 1.8 |
| P/E percentile vs own 5y | 85th | 12th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -20.9% | -61.3% |
| Net profit growth (YoY) | -110.8% | -253.0% |
| Gross margin | – | – |
| Operating margin | 9.2% | -633.0% |
| Net margin | 51.6% | -560.9% |
| Return on equity | 20.9% | -42.7% |
| Analyst target vs. price | – | +157.0% |
| Analyst buy share | – | 100% |
| RSI (14) | – | 45 |
| 30-day volatility | – | 58.0% |
| Max drawdown, 1 year | – | -61.5% |
| Trend read | – | Strong downtrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GLUE is the largest of the group by market value.
- TBPH is growing revenue fastest.
- TBPH keeps the most profit per dollar of sales.